United States was Jazz Pharmaceuticals’s largest region in fiscal 2025, bringing in $3.83B of $4.27B (90%).
| Geography | FY 2009 | FY 2010 | FY 2011 | FY 2012 | FY 2013 | FY 2014 | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $3.37B | $3.49B | $3.66B | $3.83B | |||||||||||||
| Europe | $239.64M | $269.24M | $312.71M | $341.12M | |||||||||||||
| Other | $49.36M | $74.98M | $96.14M | $94.87M | |||||||||||||
| All Other | — | — | — | — | |||||||||||||
| Total | $3.66B | $3.83B | $4.07B | $4.27B |
Jazz Pharmaceuticals brought in $4.27B from its three regions in fiscal 2025, the year ended December 31, 2025. That was up 4.9% from $4.07B in fiscal 2024. United States was the largest at $3.83B (89.8%), ahead of Europe at $341.12M (8.0%) and Other at $94.87M (2.2%).
Compared with fiscal 2024, Europe grew fastest, up 9.1% to $341.12M, while Other fell the most, down 1.3% to $94.87M. From fiscal 2022 to 2025, combined revenue from these regions grew from $3.66B to $4.27B, a compound annual growth rate of 5.3%. United States' share of the total fell from 92.1% to 89.8%.
Xywav was Jazz Pharmaceuticals’s largest product and service line in fiscal 2023, bringing in $1.27B of $3.83B (33%).
| Product and Service | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2022 | FY 2023 |
|---|---|---|---|---|---|---|---|
| Total Oxybate | — | — | — | ||||
| Total Neuroscience | — | — | — | ||||
| Xyrem | $1.74B | $1.02B | $569.73M | ||||
| Epidiolex/Epidyolex | — | $736.40M | $845.47M | ||||
| Xywav | $15.26M | $958.43M | $1.27B | ||||
| Rylaze/Enrylaze | — | $281.66M | $394.23M | ||||
| Zepzelca | $90.38M | $269.91M | $289.53M | ||||
| Erwinaze/Erwinase | $147.14M | — | — | ||||
| Defitelio/Defibrotide | $195.84M | $194.29M | $184.00M | ||||
| Vyxeos | $121.11M | $127.98M | $147.50M | ||||
| High-Sodium Oxybate Ag Royalty Revenue | — | — | $75.92M | ||||
| Prialt | — | — | — | ||||
| Other | $6.84M | $6.64M | $13.85M | ||||
| Sunosi | $28.33M | $28.84M | — | ||||
| Other Royalty & Contract Revenues | — | $17.95M | $21.34M | ||||
| Royalties & Contract Revenues | $16.91M | — | — | ||||
| Sativex | — | $16.83M | $19.67M | ||||
| Total | $2.36B | $3.66B | $3.83B |
Jazz Pharmaceuticals brought in $3.83B from its 11 product and service lines in fiscal 2023, the year ended December 31, 2023. Jazz Pharmaceuticals regrouped these lines after fiscal 2022, so the total does not compare directly with that year's $3.66B. Xywav was the largest at $1.27B (33.2%), ahead of Epidiolex/Epidyolex at $845.47M (22.1%) and Xyrem at $569.73M (14.9%). The other eight lines brought in $1.15B combined.
Compared with fiscal 2022, Rylaze/Enrylaze grew fastest, up 40.0% to $394.23M, while Xyrem fell the most, down 44.2% to $569.73M.
Jazz Pharmaceuticals began breaking out Epidiolex/Epidyolex in fiscal 2022, Rylaze/Enrylaze in fiscal 2022, High-Sodium Oxybate Ag Royalty Revenue in fiscal 2023 and Other Royalty & Contract Revenues in fiscal 2022. Jazz Pharmaceuticals stopped reporting Erwinaze/Erwinase ($147.14M in fiscal 2020), Sunosi ($28.84M in fiscal 2022) and Royalties & Contract Revenues ($16.91M in fiscal 2020) as separate lines.
Jazz Pharmaceuticals (JAZZ) reports its revenue by geography and by product and service. In fiscal 2025, United States was its largest region, bringing in $3.83B (89.8% of the total), followed by Europe at $341.12M (8.0%).
United States was Jazz Pharmaceuticals' largest region in fiscal 2025, bringing in $3.83B, or 89.8% of the $4.27B total across its three regions.
Xywav was Jazz Pharmaceuticals' largest product and service line in fiscal 2023, bringing in $1.27B, or 33.2% of the $3.83B total across its 11 product and service lines.
Among Jazz Pharmaceuticals' regions that make up at least 2% of revenue, Europe grew fastest in fiscal 2025, up 9.1% from $312.71M to $341.12M.
Every figure comes from Jazz Pharmaceuticals' annual financial filings, as reported. Each line keeps the name Jazz Pharmaceuticals gives it, and years follow its fiscal calendar.
Jazz Pharmaceuticals' revenue by geography goes back to fiscal 2009, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.